NASDAQ: ENGN

enGene Holdings Inc.

Healthcare | Biotechnology

No licensed closing price on file for ENGN. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

enGene Holdings Inc. (NASDAQ: ENGN) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 05:10 UTC.

What enGene Holdings Inc. does

The company is developing detalimogene and a genetic medicine platform focused on treating bladder cancer and mucosal tissue diseases. Genetic medicine is an emerging field with few approved therapies, and the company faces significant technical and developmental risks including unproven technologies, manufacturing challenges, and regulatory uncertainties. The company has limited financial and human resources and concentrates its research on detalimogene while building internal capabilities or partnering with external service providers.

Summarized from enGene Holdings Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Charts

Charts are in the appInteractive charts for ENGN are available in Oxford Ledge.
Open ENGN in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-09-24

2026-09-24Interim Chief Medical OfficerPurchase5,102$10.1K
2026-06-17Interim Chief Medical OfficerStock Option (Right to Buy)Award31,000—
2026-06-17DirectorStock Option (Right to Buy)Award31,000—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q1

PERCEPTIVE ADVISORS LLC5,827,506$39.69M-0.7%
Cormorant Asset Management, LP4,000,000$36.12M+72.2%
Siren, L.L.C.5,253,159$35.77M+57.5%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2026-07-16Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersRichard GlickmanEstimatedSEC 8-K →
2024-10-21Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersAnthony CheungEstimatedSEC 8-K →
2024-07-24Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment - Slideshow
Seeking Alpha Feed2026-10-19
enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path
marketbeat.com2026-10-16
enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment Transcript
Seeking Alpha Feed2026-10-15
enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha Feed2026-09-14
enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The Market
Seeking Alpha Feed2026-09-10

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ENGN and 5,000+ tickers.

Create a free account — keep ENGN

For your agent

GET /api/data?ticker=ENGN

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt